Zhejiang Hisoar Pharmaceutical Inkomsten in het verleden
Verleden criteriumcontroles 0/6
Zhejiang Hisoar Pharmaceutical's earnings have been declining at an average annual rate of -72.6%, while the Pharmaceuticals industry saw earnings growing at 9% annually. Revenues have been declining at an average rate of 5.4% per year.
Belangrijke informatie
-72.6%
Groei van de winst
-74.1%
Groei van de winst per aandeel
| Pharmaceuticals Groei van de industrie | 10.9% |
| Inkomstengroei | -5.4% |
| Rendement op eigen vermogen | -6.8% |
| Nettomarge | -19.0% |
| Laatste winstupdate | 30 Sep 2024 |
Recente prestatie-updates uit het verleden
Recent updates
Zhejiang Hisoar Pharmaceutical Co., Ltd.'s (SZSE:002099) Price Is Out Of Tune With Revenues
Sep 27
Does Zhejiang Hisoar Pharmaceutical (SZSE:002099) Have A Healthy Balance Sheet?
Aug 30Zhejiang Hisoar Pharmaceutical (SZSE:002099) Has Debt But No Earnings; Should You Worry?
May 27Zhejiang Hisoar Pharmaceutical Co., Ltd.'s (SZSE:002099) Shares Climb 28% But Its Business Is Yet to Catch Up
Mar 03Opbrengsten en kosten
Hoe Zhejiang Hisoar Pharmaceutical geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Sep 24 | 1,940 | -369 | 335 | 120 |
| 30 Jun 24 | 2,014 | -401 | 343 | 117 |
| 31 Mar 24 | 2,066 | -430 | 337 | 115 |
| 31 Dec 23 | 2,172 | -420 | 332 | 116 |
| 30 Sep 23 | 2,310 | -158 | 301 | 129 |
| 30 Jun 23 | 2,433 | -64 | 342 | 136 |
| 31 Mar 23 | 2,534 | 43 | 383 | 141 |
| 01 Jan 23 | 2,704 | 88 | 425 | 145 |
| 30 Sep 22 | 2,765 | 226 | 466 | 149 |
| 30 Jun 22 | 2,764 | 206 | 518 | 154 |
| 31 Mar 22 | 2,647 | 125 | 522 | 159 |
| 01 Jan 22 | 2,485 | 95 | 574 | 165 |
| 30 Sep 21 | 2,310 | 34 | 558 | 166 |
| 30 Jun 21 | 2,352 | 115 | 527 | 153 |
| 31 Mar 21 | 2,538 | 272 | 484 | 146 |
| 31 Dec 20 | 2,471 | 320 | 465 | 132 |
| 30 Sep 20 | 2,518 | 443 | 444 | 123 |
| 30 Jun 20 | 2,517 | 541 | 409 | 123 |
| 31 Mar 20 | 2,685 | 673 | 408 | 118 |
| 31 Dec 19 | 2,941 | 771 | 394 | 123 |
| 30 Sep 19 | 3,030 | 812 | 407 | 122 |
| 30 Jun 19 | 3,085 | 825 | 408 | 119 |
| 31 Mar 19 | 2,940 | 763 | 416 | 117 |
| 31 Dec 18 | 2,719 | 605 | 371 | 111 |
| 30 Sep 18 | 2,651 | 540 | 368 | 118 |
| 30 Jun 18 | 2,447 | 375 | 304 | 167 |
| 31 Mar 18 | 2,335 | 271 | 297 | 139 |
| 31 Dec 17 | 2,309 | 342 | 323 | 114 |
| 30 Sep 17 | 2,251 | 76 | 388 | 77 |
| 30 Jun 17 | 2,376 | 165 | 477 | 0 |
| 31 Mar 17 | 2,376 | 208 | 511 | 0 |
| 31 Dec 16 | 2,434 | 225 | 508 | 0 |
| 30 Sep 16 | 2,493 | 500 | 469 | 0 |
| 30 Jun 16 | 2,475 | 489 | 470 | 0 |
| 31 Mar 16 | 2,486 | 489 | 467 | 0 |
| 31 Dec 15 | 2,464 | 517 | 468 | 0 |
| 30 Sep 15 | 2,355 | 496 | 464 | 0 |
| 30 Jun 15 | 2,036 | 378 | 379 | 0 |
| 31 Mar 15 | 1,669 | 211 | 310 | 0 |
| 31 Dec 14 | 1,319 | 54 | 259 | 0 |
| 30 Sep 14 | 1,158 | -51 | 220 | 0 |
| 30 Jun 14 | 1,126 | -77 | 224 | 0 |
| 31 Mar 14 | 1,135 | -82 | 223 | 0 |
| 31 Dec 13 | 1,161 | -82 | 211 | 0 |
Kwaliteitswinsten: 002099 is currently unprofitable.
Groeiende winstmarge: 002099 is currently unprofitable.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: 002099 is unprofitable, and losses have increased over the past 5 years at a rate of 72.6% per year.
Versnelling van de groei: Unable to compare 002099's earnings growth over the past year to its 5-year average as it is currently unprofitable
Winst versus industrie: 002099 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-1.2%).
Rendement op eigen vermogen
Hoge ROE: 002099 has a negative Return on Equity (-6.81%), as it is currently unprofitable.